In these early medical trials bevacizumab showed antitumor activity in breast, colon, and lung cancer and identified several toxicities, like bleeding, thrombosis, hypertension, and proteinuria. The extension review was initiated in response to requests from sufferers and investigators. All sufferers who concluded ≥ 1 yr of bevacizumab therapy inside the https://augustagkps.blogdanica.com/20052193/what-does-pf00356231-mean